Search

Your search keyword '"Daas A"' showing total 752 results
Start Over "Daas A" Publisher elsevier bv
752 results on '"Daas A"'

1. THU-419 Regression of hepatic fibrosis in patients with chronic hepatitis C treated with direct-acting antivirals (DAAs). A long-term, prospective, observational study

Author

Avramopoulou, Evdoxia, primary, Tsounis, Efthymios, additional, Kanaloupitis, Stavros, additional, Zisimopoulos, Konstanitnos, additional, Kalafateli, Maria, additional, Aggeletopoulou, Ioanna, additional, Sotiropoulos, Christos, additional, Kafentzi, Theodora, additional, Geramoutsos, Georgios, additional, Ampazis, Odysseas, additional, Diamantopoulou, Georgia, additional, Tsintoni, Angeliki, additional, Thomopoulos, Konstantinos, additional, and Triantos, Christos, additional

Published
2024
Full Text
View/download PDF

3. Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV

Author

Lara-Aguilar, Violeta, primary, Valle-Millares, Daniel, additional, Crespo-Bermejo, Celia, additional, Grande-García, Sergio, additional, Llamas-Adán, Manuel, additional, Cortijo-Alfonso, María Engracia, additional, Martín-Carbonero, Luz, additional, Domínguez, Lourdes, additional, Ryan, Pablo, additional, de los Santos, Ignacio, additional, Bartolomé-Sánchez, Sofía, additional, Vidal-Alcántara, Erick Joan, additional, Jiménez-Sousa, María Angeles, additional, Fernández-Rodríguez, Amanda, additional, and Briz, Verónica, additional

Published
2023
Full Text
View/download PDF

4. Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt

Author

Mohamed S. Abdelbary, Reham Samir, Saeed M. El-Nahaas, Rasha M.H. Shahin, Mohammad El-Sayed, Yasmine Gaber, Omnia Tantawi, Naglaa A. Zayed, and Ayman Yosry

Subjects
Hepatology
Abstract

Concerns about HBV reactivation (HBVr) have been raised with the introduction of DAA for HCV treatment. The aim of the study was to assess the risk of HBVr in chronic HCV patients during or after DAA.A cohort of 166 chronic HCV patients who were treated with SOF-based DAA regimens and initially positive for HBcAb total were evaluated; 10 HBsAg-positive, 156 had past HBV exposure (HBsAg-negative/HBcAb-positive). Laboratory investigations, including liver functions tests, HBV-DNA, LSM by Transient elastography, and ARFI together with serum markers of fibrosis; APRI and FIB-4 were done at baseline and after 12 weeks of DAAs therapy. HBV-DNA levels and liver functions were monitored for assessment of HBVr.Virological HBVr was diagnosed by ≥ 1 log10 IU/ml HBV-DNA levels in 2/166 patients (1.2%) among the whole HCV cohort, who were initially positive for HBsAg; 20%. Clinical HBVr (3 folds liver enzyme elevation) was detected in one patient with virological HBVr. Conversely, none of past HBV-infected patients experienced HBVr. All patients achieved SVR12 and had a significant decline in serum transaminases, bilirubin, APRI, and LSM measurements after HCV eradication.HBVr might be considered after successful eradication of HCV following DAAs therapy, especially among patients who are positive for HBsAg, while past HBV infection does not seem to be a predisposing condition to HBVr.

Published
2022
Full Text
View/download PDF

6. Efficacy and Safety of Adding Ribavirin to Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C Infection- a Systematic Review and Meta-Analysis

Author

Hamran, Shahd, primary, Al-Rajhi, Amani, additional, Jasim, Kawther, additional, Al-Theyab, Majed, additional, Elahtam, Mohammed, additional, Al-Hail, Mooza, additional, Al-Fahaidi, Wadha, additional, Dweidri, Yara, additional, Elzouki, Abdelnaser, additional, and Chivese, Tawanda, additional

Published
2023
Full Text
View/download PDF

7. Antioxidants benefits in hepatitis C infection in the new DAAs era

Author

Sonia A Lozano-Sepulveda, Ana R. Rincón-Sanchez, and Ana M. Rivas-Estilla

Subjects
Male, Antioxidant, medicine.medical_treatment, Specialties of internal medicine, DAAs era, Hepacivirus, Pharmacology, Antiviral Agents, Severity of Illness Index, Antioxidants, 03 medical and health sciences, 0302 clinical medicine, In vivo, medicine, Humans, Hepatology, business.industry, General Medicine, Hepatitis C, Hepatitis C, Chronic, Prognosis, medicine.disease, In vitro, Treatment Outcome, RC581-951, 030220 oncology & carcinogenesis, Dietary Supplements, Female, 030211 gastroenterology & hepatology, Reactive Oxygen Species, business
Abstract

Some of the evidence on whether antioxidant supplements are effective in treatment of liver diseases is contradictory. Here we perform a descriptive analysis of the available data in vivo and in vitro of the possible antiviral action and controversy of several antioxidant molecules against HCV.

Published
2019
Full Text
View/download PDF

8. Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients

Author

Virseda-Berdices, Ana, Rojo, David, Martinez, Isidoro, Berenguer, Juan, González-García, Juan, Brochado-Kith, Oscar, Fernandez-Rodriguez, Amanda, Díez, Cristina, Hontañon, Víctor, Pérez-Latorre, Leire, Micán, Rafael, Barbas, Coral, Resino, Salvador, Jimenez-Sousa, Maria Angeles, ESCORIAL Study Group, Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad (España), Red de Investigación Cooperativa en Investigación en Sida, Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas), Sistema Nacional de Salud (España), and Ministerio de Ciencia, Innovación y Universidades (España)

Subjects
Inflammation, Liver Cirrhosis, Male, Taurocholic Acid, Pharmacology, HIV, HIV Infections, General Medicine, Middle Aged, Chronic hepatitis C, DAAs therapy, Antiviral Agents, Hepatitis C, Severity of Illness Index, Cirrhosis, HCV elimination, Spain, Phosphatidylcholines, Metabolomics, Humans, Female, Longitudinal Studies, Biomarkers
Abstract

Background: A better understanding of the evolution of cirrhosis after hepatitis C virus (HCV) clearance is essential since the reversal of liver injury may not happen. We aimed to assess the evolution of plasma metabolites after direct-acting antivirals (DAAs) therapy and their association with liver disease scores in HIV/HCV-coinfected patients with advanced HCV-related cirrhosis. Methods: We performed a prospective study in 49 cirrhotic patients who started DAAs therapy. Data and samples were collected at baseline and 36 weeks after SVR. Metabolomics analysis was carried out using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. Inflammation-related biomarkers were analyzed using ProcartaPlex Immunoassays. Results: At 36 weeks after SVR, patients experienced significant decrease in taurocholic acid, 2,3-butanediol, and LPC(18:0); while several phosphatidylcholines (LPC(16:1), LPC(18:1), LPC(20:4), and PC(16:0/9:0(CHO))/PC(16:0/9:0(COH)), 2-keto-n-caproic acid/2-keto-isocaproic acid and N-methyl alanine increased, compared to baseline. The plasma decrease in taurocholic acid was associated with a reduction in Child-Turcotte-Pugh (CTP) (AMR=3.39; q-value=0.006) and liver stiffness measurement (LSM) (AMR=1.06; q-value

Published
2022
Full Text
View/download PDF

11. Systemic adipokines, hepatokines and interleukin-6 in HCV-monoinfected and HCV/HIV coinfected patients treated with direct antiviral agents (DAAs)

Author

Gabriella d'Ettorre, Miriam Lichtner, Paolo Pavone, Giulia Alfieri, Claudia Mascia, Vincenzo Vullo, Tiziana Tieghi, Claudia Pinacchio, Saeid Najafi Fard, Giuseppe Corano-Scheri, and Claudio Maria Mastroianni

Subjects
Male, alpha-2-HS-Glycoprotein, Human immunodeficiency virus (HIV), MEDLINE, Adipokine, HIV Infections, medicine.disease_cause, Antiviral Agents, Selenoprotein P, Diabetes mellitus, hcv, medicine, Humans, Interleukin 6, adipokines, cytokines, daas, diabetes, hepatokines, hepatology, gastroenterology, Hepatology, biology, Coinfection, Interleukin-6, business.industry, Gastroenterology, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, Immunology, biology.protein, Female, Adiponectin, business
Published
2018
Full Text
View/download PDF

14. Benign course of HBV reactivations during DAAs in untreated ENI with HBV-HCV co-infections correlates with different HBsAg kinetics compared to NAs treated CHB patients

Author

Colombatto, Piero, primary, Palmisano, Elena, additional, Ricco, Gabriele, additional, Cavallone, Daniela, additional, Oliveri, Filippo, additional, Coco, Barbara, additional, Salvati, Antonio, additional, Romagnoli, Veronica, additional, Surace, Lidia, additional, Vatteroni, Maria Linda, additional, Pistello, Mauro, additional, Virdis, Agostino, additional, Bonino, Ferruccio, additional, and Brunetto, Maurizia, additional

Published
2022
Full Text
View/download PDF

16. Development and initial validation of a short form of the diabetes acceptance and Action Scale: The DAAS-Revised (DAAS-R)

Author

David Gillanders and Estelle Barker

Subjects
050103 clinical psychology, Organizational Behavior and Human Resource Management, Health (social science), factor analysis, Acceptance and commitment therapy, Health(social science), 03 medical and health sciences, Behavioral Neuroscience, 0302 clinical medicine, Cronbach's alpha, Intervention (counseling), Diabetes mellitus, medicine, Experiential avoidance, 0501 psychology and cognitive sciences, Applied Psychology, Ecology, Evolution, Behavior and Systematics, Type 1 diabetes, diabetes, 05 social sciences, scale development, medicine.disease, Test theory, 030227 psychiatry, acceptance & commitment therapy, test theory, Scale (social sciences), measurement, Psychology, Clinical psychology
Abstract

Background: Diabetes is a condition that requires substantial behavioural management and psychological adjustment. Acceptance and Commitment Therapy (ACT) has shown promise as an effective intervention for people with diabetes. Measures of acceptance in diabetes have been developed, though they are long, which discourages their use in routine clinical work and increases item burden in research studies. In addition, different scales have been developed for children and adults, making it difficult to compare diabetes acceptance across the lifespan. This study aimed to develop a short form of the Diabetes Acceptance and Action Scale that would be suitable for administration across all ages. Method: People with diabetes were recruited via social media, support organisations and charities as well as clinical services. They completed an online survey measuring demographic and clinical data, the Diabetes Acceptance & Action Scale, Problems in Diabetes Short Form, Self-Care Inventory Revised, Brief Experiential Avoidance Questionnaire, Cognitive Fusion Questionnaire and Engaged Living Scale. Results: Five hundred and thirty-one participants with diabetes responded to the online survey. The sample was 78% British, and 67% female. Seventy percent of the sample had Type 1 diabetes and 30% had Type 2. The scale was successfully reduced to a nine item, one factor scale, with excellent model fit. Cronbach's α was 0.9 and the scale correlated very highly with the original DAAS (r = 0.92, p < .0001). Initial convergent validity was established through moderate to strong correlations with diabetes related distress (r = −0.76, p < .0001) and diabetes self-care (r = 0.33, p < .0001). Initial concurrent validity was established through strong correlations with Experiential Avoidance (r = −0.64, p < .0001), Cognitive Fusion (r = −0.65, p < .0001) and Engaged Living (r = 0.58, p < .0001). Conclusion: The DAAS-R is a brief scale, with equivalent psychometric properties to the original 42-item scale. Its brevity should give it greater utility in both clinical and research settings.

Published
2019
Full Text
View/download PDF

18. Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt

Author

Ekram W. Abd El-Wahab, Amira M. Kotkat, Ashraf Mikheal, Hesham A. K. Ayoub, Mohamed Fadl, and Aziza A. Shorbila

Subjects
Microbiology (medical), medicine.medical_specialty, Cirrhosis, Epidemiology, Liver fibrosis, Serum albumin, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Chronic hepatitis, Fibrosis, Internal medicine, medicine, 030212 general & internal medicine, Noninvasive biomarkers, 030219 obstetrics & reproductive medicine, biology, medicine.diagnostic_test, business.industry, Proportional hazards model, Public Health, Environmental and Occupational Health, medicine.disease, Infectious Diseases, Liver biopsy, biology.protein, business
Abstract

Background The scale of HCV problem in Egypt prioritized the development of a national control strategy that employs the use of locally manufactured generic direct-acting antivirals (DAAs). Achieving sustained virologic response in chronic HCV patients is the key for preventing fibrosis progression and ultimately its resolution. Objective(s) To evaluate impact of generic DAAs on liver fibrosis in chronic HCV patients using some non-invasive biomarkers (NIBMs). Methods A total of 280 chronic HCV patients (18 treatment experienced and 262 naive) were enrolled and received the standard of care. All patients were clinically evaluated before starting treatment and at 4, 12 and 24 weeks of treatment. Results The sensitivity and the specificity of the tested NIBMs for predicting cirrhosis versus liver ultrasound ranged between 75.0-79.6% and 59.4–67.2% respectively. All NIBMs showed significant linear decline during the treatment and follow up periods among responders but tended to fluctuate in values toward an increase among non-responders. In cox regression analysis, normal baseline ALT, AST, total serum cholesterol, serum albumin, WBCS, prothrombin activity and early stages of liver fibrosis predicted improvement in liver fibrosis by 1.5–2 folds. The mean probability of recovery at 1, 3, 6 months varied between the different scores and ranged from 0.059 to 0.637, 0.125–0.741, 0.538–0.951 respectively. Conclusion The results provide prognostic data on the improvement in liver fibrosis over the treatment course and follow up periods without the need for a liver biopsy. Early detection and management of HCV infection should be emphasized to maximize the benefits of the treatment.

Published
2020
Full Text
View/download PDF

19. Effect of treatment with direct antiviral agents (DAAs) on glycemic control in patients with type 2 diabetes mellitus & hepatitis C virus genotype 4

Author

Amal El-Bendary, Nashwa Mohamed Abo Alnasr, Hassan Yousef Zied, Sherief Abd-Elsalam, and Rasha Youssef Hagag

Subjects
Adult, Blood Glucose, Male, 0301 basic medicine, medicine.medical_specialty, Sofosbuvir, Endocrinology, Diabetes and Metabolism, Physical examination, Hepacivirus, Antiviral Agents, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Insulin resistance, Diabetes mellitus, Internal medicine, Internal Medicine, Humans, Medicine, Medical history, Prospective Studies, Prospective cohort study, Glycemic, medicine.diagnostic_test, business.industry, Type 2 Diabetes Mellitus, General Medicine, Hepatitis C, Chronic, Middle Aged, medicine.disease, 030104 developmental biology, Diabetes Mellitus, Type 2, Female, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract

Background and aims It is widely recognized that chronic hepatitis C is a metabolic disease that is strongly associated with type 2 diabetes mellitus (T2DM) and insulin resistance (IR). The evidence behind the effect of Direct Anti-Viral Agents (DAAs) therapy on T2DM is conflicting. The aim of the present study was to evaluate the effect of treatment with DAAs on glycemic control in patients with type-2 diabetes mellitus and chronic hepatitis C virus genotype 4. Methods This study was a prospective study that conducted on 100 patients with chronic hepatitis C and Type-2 diabetes mellitus, selected from Kafr El-Sheikh Liver Research Center treated with Direct Anti-Viral Agents (DAAs) during the period from September 1, 2017 to last of August 2018. All patients in the study were subjected to the following: Full history taking stressing on the age, gender, previous treatment; clinical examination and laboratory investigations. HBA1C was assessed before and after DAAs treatment. Results In the present study, there was a significant decrease of baseline fasting blood glucose levels after treatment when compared with before treatment. Also, there was a significant decrease of 2 h post prandial blood glucose after treatment when compared with before treatment. There was significant decrease of HBA1c levels after treatment when compared with before treatment. Conclusions DAAs treatment significantly improved the fasting blood glucose and help better glycemic control. This study augments the importance and the benefits of new Direct Anti-Viral Agents interferon free regimens in diabetic HCV infected patients.

Published
2020
Full Text
View/download PDF

21. 328: REAL-WORLD TREATMENT OUTCOME WITH PROTEASE INHIBITOR (PI) VS NON-PI DIRECT ACTING ANTIVIRALS (DAAS) IN DECOMPENSATED HCV CIRRHOSIS: A REAL-C STUDY

Author

Wong, Yu Jun, primary, Tran, Sally, additional, Huang, Chung-Feng, additional, Hsu, Yao-Chun, additional, Preda, Carmen M., additional, Toyoda, Hidenori, additional, Liu, Joanne, additional, Jun, Dae Won, additional, Landis, Charles, additional, Huang, Daniel, additional, Gila, Andrei B., additional, Negoita, Livia, additional, Yasuda, Satoshi, additional, Tseng, Cheng-Hao, additional, Tsai, Pei-Chien, additional, Uojima, Haruki, additional, Nozaki, Akito, additional, Chuma, Makoto, additional, Atsukawa, Masanori, additional, itokawa, norio, additional, Iio, Etsuko, additional, Lam, Carla, additional, Watanabe, Tsunemasa, additional, Keisuke, Yokohama, additional, Abe, Hiroshi, additional, Enomoto, Masaru, additional, Tamori, Akihiro, additional, Lee, Dong-Hyun, additional, Jun, Mijung, additional, Maeda, Mayumi, additional, Nakanishi, Akiko, additional, Yeh, Ming-Lun, additional, Chuang, Wan-Long, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Ishikawa, Toru, additional, Takaguchi, Koichi, additional, Senoo, Tomonori, additional, Trinh, Huy N., additional, Takahashi, Hirokazu, additional, Eguchi, Yuichiro, additional, Quek, Sabrina X., additional, Haga, Hiroaki, additional, Ogawa, Eiichi, additional, Wong, Grace L., additional, Buti, Maria, additional, Fukunishi, Shinya, additional, Ueno, Yoshiyuki, additional, Yuen, Man-Fung, additional, Tanaka, Yasuhito, additional, Lim, Seng Gee, additional, Cheung, Ramsey, additional, Yu, Ming-Lung, additional, and Nguyen, Mindie H., additional

Published
2022
Full Text
View/download PDF

24. Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort

Author

Salomone, F., primary, Cacciola, I., additional, Petta, S., additional, Calvaruso, V., additional, Micek, A., additional, Madonia, S., additional, Grova, M., additional, Distefano, M., additional, Cannavò, M., additional, Di Rosolini, M.A., additional, Digiacomo, A., additional, Di Lorenzo, F., additional, Bertino, G., additional, Licata, A., additional, Latteri, F., additional, Benanti, F., additional, Averna, A., additional, Guarneri, L., additional, Scalisi, I., additional, Iacobello, C., additional, Montineri, A., additional, Colletti, P., additional, Cartabellotta, F., additional, Davì, A., additional, Russello, M., additional, Scifo, G., additional, Squadrito, G., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2022
Full Text
View/download PDF

27. HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization

Author

Valle-Millares, Daniel, primary, Brochado-Kith, Óscar, additional, Gómez-Sanz, Alicia, additional, Martín-Carbonero, Luz, additional, Ryan, Pablo, additional, De los Santos, Ignacio, additional, Castro, Juan M., additional, Troya, Jesús, additional, Mayoral-Muñoz, Mario, additional, Cuevas, Guillermo, additional, Martínez-Román, Paula, additional, Sanz-Sanz, Jesús, additional, Muñoz-Muñoz, María, additional, Jiménez-Sousa, María Á, additional, Resino, Salvador, additional, Briz, Verónica, additional, and Fernández-Rodríguez, Amanda, additional

Published
2022
Full Text
View/download PDF

28. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)

Author

Cespiati, Annalisa, primary, Petta, Salvatore, additional, Lombardi, Rosa, additional, Di Marco, Vito, additional, Calvaruso, Vincenza, additional, Bertelli, Cristina, additional, Pisano, Giuseppina, additional, Fatta, Erika, additional, Sigon, Giordano, additional, Iuculano, Federica, additional, Crapanzano, Luciano, additional, Gibilaro, Gerlando, additional, Francione, Paolo, additional, Craxì, Antonio, additional, Fargion, Silvia, additional, and Fracanzani, Anna Ludovica, additional

Published
2021
Full Text
View/download PDF

30. AF.90 RISK FACTORS FOR LIVER DECOMPENSATION AND HCC IN HCV-CIRRHOTIC PATIENTS AFTER DAAS: A MULTICENTER PROSPECTIVE STUDY

Author

Guarino, M., primary, Pontillo, G., additional, Federico, A., additional, Marignani, M., additional, Cannavò, M., additional, Pignata, L., additional, Cossiga, V., additional, Capasso, M., additional, Dallio, M., additional, Begini, P., additional, Benigno, R., additional, Lombardo, F., additional, Stroffolini, T., additional, and Morisco, F., additional

Published
2021
Full Text
View/download PDF

31. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

Author

Sasso, Ferdinando Carlo, primary, Pafundi, Pia Clara, additional, Caturano, Alfredo, additional, Galiero, Raffaele, additional, Vetrano, Erica, additional, Nevola, Riccardo, additional, Petta, Salvatore, additional, Fracanzani, Anna Ludovica, additional, Coppola, Carmine, additional, Di Marco, Vito, additional, Solano, Antonio, additional, Lombardi, Rosa, additional, Giordano, Mauro, additional, Craxi, Antonio, additional, Perrella, Alessandro, additional, Sardu, Celestino, additional, Marfella, Raffaele, additional, Salvatore, Teresa, additional, Adinolfi, Luigi Elio, additional, and Rinaldi, Luca, additional

Published
2021
Full Text
View/download PDF

32. Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort

Author

F. Salomone, I. Cacciola, S. Petta, V. Calvaruso, A. Micek, S. Madonia, M. Grova, M. Distefano, M. Cannavò, M.A. Di Rosolini, A. Digiacomo, F. Di Lorenzo, G. Bertino, A. Licata, F. Latteri, F. Benanti, A. Averna, L. Guarneri, I. Scalisi, C. Iacobello, A. Montineri, P. Colletti, F. Cartabellotta, A. Davì, M. Russello, G. Scifo, G. Squadrito, G. Raimondo, A. Craxì, and V. Di Marco

Subjects
Hepatology, Gastroenterology
Published
2022
Full Text
View/download PDF

37. New onset steatosis but not persistent steatosis prevents hepatic fibrosis improvement after viral eradication by direct-acting antiviral therapy (DAAs) in patients with chronic hepatitis C: Evaluation by controlled attenuation parameter (CAP) and liver stiffness measurement LSM

Author

Cespiati, A., primary, Petta, S., additional, Lombardi, R., additional, Di Marco, V., additional, Calvaruso, V., additional, Bertelli, C., additional, Pisano, G., additional, Fatta, E., additional, Sigon, G., additional, Iuculano, F., additional, Crapanzano, L., additional, Gibilaro, G., additional, Francione, P., additional, Craxì, A., additional, Fargion, S., additional, and Fracanzani, A.L., additional

Published
2021
Full Text
View/download PDF

40. Coagulation balance and liver damage in non-cirrhotic patients with chronic hepatitis C after eradication by Direct-acting Antiviral Agents (DAAs)

Author

Sigon, G., primary, D'Ambrosio, R., additional, Clerici, M.G., additional, Pisano, G., additional, Chantarangkul, V., additional, Sollazzi, R., additional, Cespiati, A., additional, Iuculano, F., additional, Lombardi, R., additional, Peyvandi, F., additional, Lampertico, P., additional, Fargion, S., additional, Tripodi, A., additional, and Fracanzani, A.L., additional

Published
2021
Full Text
View/download PDF

41. HBV/HCV Coinfection in the Era of HCV-DAAs

Author

Rashed Abdelaal, Beshoy Yanny, and Mohamed El Kabany

Subjects
Liver Cirrhosis, Male, Hepatitis B virus, Carcinoma, Hepatocellular, Hepatitis C virus, Comorbidity, Hepacivirus, medicine.disease_cause, Risk Assessment, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Prevalence, medicine, Humans, Hepatology, Coinfection, Transmission (medicine), business.industry, Liver Neoplasms, virus diseases, Hepatitis C, Hepatitis B, medicine.disease, Survival Analysis, Virology, United States, digestive system diseases, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Disease Progression, Female, 030211 gastroenterology & hepatology, business
Abstract

Epidemiologic studies suggest that 10% to 15% of patients infected with hepatitis C virus (HCV) are coinfected with hepatitis B virus (HBV) in the United States as a result of the shared modality of transmission, but the true prevalence is not known. The progression of liver disease to cirrhosis and hepatocellular carcinoma is generally faster in patients who are coinfected, and HCV is usually more predominant. Immunosuppression of the host or eradication of hepatitis C can change this paradigm, causing hepatitis B reactivation. This review describes HCV-HBV viral interactions, risks for reactivation, screening, and society guidelines for surveillance and treatment.

Published
2019
Full Text
View/download PDF

47. No restrictions should be placed on future treatment for patients who discontinue DAAs on their first or second attempt. A real world experience from the TraP HepC initiative in Iceland

Author

Olafsson, Sigurdur, primary, Löve, Thorvardur J., additional, Fridriksdottir, Ragnheidur H., additional, Tyrfingsson, Thorarinn, additional, Runarsdottir, Valgerdur, additional, Hansdottir, Ingunn, additional, Bergmann, Ottar M., additional, Björnsson, Einar S., additional, Johannsson, Birgir, additional, Sigurdardottir, Bryndis, additional, Löve, Arthur, additional, Baldvinsdóttir, Guðrún Erna, additional, Sigmundsdottir, Gudrun, additional, Hernandez, Ubaldo Benitez, additional, Heimisdottir, Maria, additional, and Gottfredsson, Magnús, additional

Published
2020
Full Text
View/download PDF

49. Effectiveness of new generation DAAs for HCV infection in a large cohort of Italian people who use drugs (PWID): the cleo-grecas real-world experience

Author

Messina, Vincenzo, primary, Iovinella, Vincenzo, additional, Claar, Ernesto, additional, Rosato, Valerio, additional, De Luca, Massimo, additional, Barbarini, Giorgio, additional, Cariti, Giuseppe, additional, Lupia, Tommaso, additional, Quartini, Mariano, additional, D’Offizi, Gianpiero, additional, Luzzitelli, Ilaria, additional, Parruti, Giustino, additional, Sozio, Federica, additional, Scifo, Gaetano, additional, Distefano, Marco, additional, Paolo, Tundo, additional, Benanti, Francesco, additional, Cosco, Lucio, additional, Bulla, Fabio, additional, Gimignani, Giancarlo, additional, Di Rosolini, Maria Antonietta, additional, Palitti, Valeria Pace, additional, Gentilucci, Umberto Vespasiani, additional, Ascione, Antonio, additional, Imparato, Michele, additional, Rinaldi, Luca, additional, Nevola, Riccardo, additional, Di Marco, Vito, additional, Craxì, Antonio, additional, Morbiducci, Valeria, additional, Di Lorenzo, Francesco, additional, Guarisco, Riccardo, additional, Sacco, Rodolfo, additional, and Izzi, Antonio, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results